Recombinant DNA Technology and Insulin Production by Eli Lilly

The question asks to identify the company that utilized recombinant DNA technology in 1983 to produce insulin. This achievement was a major breakthrough in biotechnology, allowing for the mass production of human insulin, a vital hormone for treating diabetes.

Before recombinant DNA technology, insulin for therapeutic use was primarily extracted from the pancreases of pigs and cattle. While effective, this process had limitations, including potential allergic reactions in some patients due to impurities or species differences, and the supply was dependent on animal availability.

Recombinant DNA technology involves taking a gene (in this case, the human insulin gene) and inserting it into another organism, such as bacteria or yeast, to produce the desired protein. The modified organism acts as a 'factory' to synthesize large quantities of the protein.

Several biotechnology companies and research institutions were working on this technology in the late 20th century. However, the first company to successfully develop and commercialize human insulin using recombinant DNA technology was Eli Lilly.

Eli Lilly introduced Humulin (human insulin, recombinant DNA origin) in 1982, receiving FDA approval. While the primary approval year is 1982, significant production and widespread availability would have continued into 1983 and beyond. The question specifically mentions 1983, aligning with the period when Eli Lilly's recombinant insulin was being produced and distributed.

Let's look at the options provided:

• Eli Lilly: This company is historically recognized as the pioneer in the production of recombinant human insulin.
• Emily Lilly: This name is not associated with the historical development of recombinant insulin production technology.
• Amy Sanger: This name is not associated with the historical development of recombinant insulin production technology. While Frederick Sanger was a Nobel laureate known for sequencing DNA, 'Amy Sanger' is not a figure prominently associated with this specific application.
• More than one of the above: Since only Eli Lilly is correctly associated, this option is incorrect.
• None of the above: Since Eli Lilly is correctly associated, this option is incorrect.

Therefore, based on the historical facts, Eli Lilly was the company responsible for producing insulin using recombinant DNA technology around 1983.

This development revolutionized diabetes treatment, offering a purer, more consistent, and scalable source of insulin compared to animal-derived versions.